Skip to main content
OpenTrials
Completed

NCT Number: NCT04799600

The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

Aim of the study is to determinate the frequency of acute renal failure in COVID-19 patients, its relationship with the severity of COVID-19 disease in ICU, and the ability to take precautions against these factors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 Acute Kidney Injury Acute Renal Failure COVID-19 Coronaviridae Infections Coronavirus Infections Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Infections Kidney Diseases Lung Diseases Male Urogenital Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Renal Insufficiency Respiratory Tract Diseases Respiratory Tract Infections Urogenital Diseases Urologic Diseases Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara City Hospital

Ankara, 06800, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients hospitalized in the intensive care unit diagnosed with COVID-19 will include in the study.

Exclusion criteria

there is no exclusion criteria

Treatment and study plan

BRESCİA-COVİD Respiratory Severity Scale

Other

KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score

Primary outcomes

  1. KDIGO criteria

    Time frame: 6 months

    KDIGO Criteria stage 1: Increase in SCr by ≥ 0.3 mg/dL within 48 hours or increase in SCr 1.5 to 1.9 times baseline which is known or presumed to have occurred within the prior 7 days Stage 2: 2.0 to 2.9 multiplied by baseline SCr;

    Stage 3: 3.0 or more multiplied by baseline; increase in SCr ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage.

  2. BRESCIA-COVID RESPIRATORY SEVERITY SCALE (BCRSS) scores

    Time frame: 6 months

    The BCRSS score (between level 0-8) is calculated from "www.mdcalc.com/brescia-covid-respiratory-severity-scale-bcrss-algorithm" according to the severity of COVID disease , respiratory rate, PaO2 level, chest x-ray, and clinical status.

Sponsors and collaborators

Lead sponsor

Ankara City Hospital Bilkent

Other

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 16, 2021
Registry last updated
Jul 27, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.